Published in Medical Letter on the CDC and FDA, November 27th, 2005
Levemir is a long-acting form of insulin that provides up to a 24-hour duration of action and has been observed in studies with adults to cause little weight change.
Novo Nordisk will launch Levemir for adults and children within the next 8 months.
Levemir was studied in a randomized, controlled clinical study of 347 children and adolescents with type 1 diabetes. The children were treated with Levemir as the baseline or "basal" insulin and with rapid acting insulin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA